Table 3.

A case-control comparison of risks of melanoma in the second Leeds case and control series (Leeds Case 2 and Leeds Control 2) in relation to VDR SNP genotypes (as the Leeds Control 2 were female we have shown the population controls for comparison (Leeds Control 1).

		Leeds Case 2	Leeds Control 1	Leeds Control 2	Leeds Case 2 versus Leeds Control 2			Leeds Case 2 versus (Leeds Control 1 + Leeds Control 2)
SNP	Genotype	n=299	n=402	n=560	OR (95% CI)	P*	Trend P†	OR (95% CI)	P*	Trend P†
Cdx2	GG	193 (64.6)	250 (62.2)	350 (62.5)	1			1
	GA	89 (29.8)	134 (33.3)	179 (32.0)	0.90 (0.66, 1.23)	0.80	0.66	0.88 (0.66, 1.18)	0.64	0.69
	AA	17 (5.7)	18 (4.5)	31 (5.5)	0.99 (0.54, 1.84)			1.08 (0.61, 1.92)
GATA	AA	87 (29.1)	137 (34.1)	198 (35.4)	1			1
	AG	151 (50.5)	188 (46.8)	261 (46.6)	1.32 (0.95, 1.82)	0.17	0.09	1.29 (0.96, 1.75)	0.18	0.11
	GG	61 (20.4)	77 (19.2)	101 (18.0)	1.37 (0.92, 2.06)			1.32 (0.91, 1.92)
FokI	CC (FF)	96 (32.1)	161 (40.1)	225 (40.2)	1			1
	CT (Ff)	139 (46.5)	176 (43.8)	255 (45.5)	1.28 (0.93, 1.75)	0.01	0.003	1.30 (0.97, 1.74)	0.009	0.002
	TT (ff)	64 (21.4)	65 (16.2)	80 (14.3)	1.88 (1.25, 2.82)			1.77 (1.23, 2.57)
BsmI	GG (bb)	110 (36.8)	134 (33.3)	175 (32.3)	1			1
	GA (Bb)	145 (48.5)	202 (50.3)	284 (50.7)	0.81 (0.59, 1.11)	0.20	0.07	0.84 (0.63, 1.12)	0.27	0.11
	AA (BB)	44 (14.7)	66 (16.4)	101 (18.0)	0.69 (0.45, 1.06)			0.74 (0.50, 1.10)
ApaI	CC (aa)	68 (22.7)	92 (22.9)	102 (18.2)	1			1
	CA (Aa)	151 (50.5)	190 (47.3)	283 (50.5)	0.80 (0.56, 1.15)	0.19	0.07	0.91 (0.65, 1.27)	0.37	0.17
	AA (AA)	80 (26.8)	120 (29.9)	175 (31.3)	0.69 (0.46, 1.03)			0.77 (0.53, 1.12)
TaqI	TT (TT)	107 (35.8)	144 (35.8)	187 (33.4)	1			1
	TC (Tt)	150 (50.2)	194 (48.3)	273 (48.8)	0.96 (0.70, 1.31)	0.34	0.21	0.99 (0.75, 1.32)	0.46	0.34
	CC (tt)	42 (14.1)	64 (15.9)	100 (17.9)	0.73 (0.48, 1.13)			0.79 (0.53, 1.19)

^†P-values from Cochran-Armitage trend test. P-values from models comparing genotype frequencies (2 degrees of freedom)